COVID - 19

June 24, 2020 | RR Baliga, MD, MBA

Question Is the receipt of colchicine among patients hospitalized with symptomatic coronavirus disease 2019 associated with clinical benefit? Findings In this randomized clinical trial of 105 patients, the rate of the primary clinical end point (clinical deterioration) was higher in the control group than in the colchicine group, and the time to clinical deterioration was shorter in the control group than in the colchicine arm. No difference was observed in the primary biochemical end point (high-sensitivity troponin concentration), but patients in the colchicine group had a smaller increase in dimerized plasma fragment D compared with patients in the control group. Meaning The hypothesis-generating findings of this study suggest a role for colchicine in the treatment of patients with coronavirus disease 2019.

May 27, 2020 | RR Baliga, MD, MBA

Masks reduce airborne transmission : Infectious aerosol particles can be released during breathing and speaking by asymptomatic infected individuals. No masking maximizes exposure, whereas universal masking results in the least exposure.

May 26, 2020 | RR Baliga, MD, MBA

BMJ: Martineau is pragmatic: “At best vitamin D deficiency will only be one of many factors involved in determining outcome of COVID-19, but it's a problem that could be corrected safely and cheaply

May 25, 2020 | RR Baliga, MD, MBA

In patients hospitalized with COVID-19 and not initially intubated, famotidine use was associated with a two-fold reduction in clinical deterioration leading to intubation or death. These findings are observational and should not be interpreted to mean that famotidine has a protective effect against COVID-19. Randomized controlled trials are underway

May 20, 2020 | RR Baliga, MD, MBA

Tamsulosin and Prazosin to prevent Cytokine Release Syndrome in COVID-19?

May 18, 2020 | RR Baliga, MD, MBA

R0, Rt, Herd-immunity, Infection fatality rate & Death Rates

May 15, 2020 | RR Baliga, MD, MBA

Kawasaki Syndrome and COVID-19 or PIMS-TS (Pediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-COV2 --30 fold increase in Kawasaki in children with Covid

March 24, 2020 | RR Baliga, MD, MBA, FRCP (Edin), FACP, FACC

COVID-19 World Health Organization (WHO) led 'SOLIDARITY' & FRENCH led 'DISCOVERY' TRIALS

March 21, 2020 | RR Baliga, MD, FRCP (Edin), FACP, FACC

Hydroxychloroquine and azithromycin as a treatment of COVID-19

March 20, 2020 | RR Baliga, MD, MBA, FRCP (Edin), FACP, FACC

COVID-19 in Patients with Heart Disease and Cancer

March 20, 2020 | RR Baliga, MD, MBA, FRCP (Edin), FACP, FACC

Convalescent Serum for Influenza Pneumonia JAMA 1918

March 19, 2020 | RR Baliga, MD, MBA, FRCP (Edin), FACP, FACC

COVID-19 Update March 19th 2020, 6 pm

March 18, 2020 | RR Baliga, MD, MBA, FRCP (Edin), FACP, FACC

Lopinavir–Ritonavir NOT Effective in Severe COVID19 | Dr RR Baliga's 'Got Knowledge Doc' PodKasts for Physicians, NEJM

March 18, 2020 | RR Baliga, MD, MBA, FRCP (Edin), FACP, FACC

Psychological Impact of Quarantine: How To Reduce it

March 16, 2020 | RR Baliga, MD, MBA, FRCP (Edin), FACP, FACC

Tocilizumab to Manage Cytokine Release Syndrome Associated with Severe COVID-19 infections

March 15, 2020 | RR Baliga, MD, MBA, FRCP (Edin), FACP, FACC

What is the impact of ACE-Inhibitors/ARBs in COVID19 patients?

March 15, 2020 | RR Baliga, MD, MBA

What is the impact of ACE-Inhibitors/ARBs in COVID19 patients?

March 15, 2020 | RR Baliga, MD, MBA, FRCP (Edin), FACP, FACC

Clinical Course & Risk Factors for Mortality of Adult Patients with Covid-19

March 2, 2020 | RR Baliga, MD, MBA

Clinical Characteristics of Covid-19 infection

Internal Medicine - Mastermedfacts

Get Free MCQ Question Every Week

Close